Generic drug maker Sandoz is challenging a ruling that it infringed a patent behind Lundbeck’s blockbuster antidepressant Lexapro, reviving a 15-year fight over the lucrative intellectual property.
Generic drug maker Sandoz is challenging a ruling that it infringed a patent behind Lundbeck’s blockbuster antidepressant Lexapro, reviving a 15-year fight over the lucrative intellectual property.
For information on rights and reprints, contact subscriptions@lawyerly.com.au